Search results for "Acquired hemophilia"

showing 6 items of 6 documents

Future directions in acquired hemophilia A

2021

Pediatricsmedicine.medical_specialtyFactor VIIIbusiness.industryImmunologyMEDLINECell BiologyHematologyAntibodies Monoclonal HumanizedHemophilia ABiochemistryAcquired HaemophiliaemicizumabAntibodies BispecificAcquired hemophiliaHumansMedicinebusiness
researchProduct

Demographic and clinical data in acquired hemophilia A

2012

Summary.  Background:  Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. Objectives:  The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. Results:  Five hundred and one (266 male, 235 female) patients from …

RegistrieMalePediatricsdiagnosismedicine.medical_treatmentHemostatic TechniqueKaplan-Meier EstimateregistryTHERAPYSettore MED/15 - Malattie Del SangueImmunosuppressive AgentIMMUNOADSORPTIONRisk FactorsPregnancy80 and overProspective StudiesRegistriesProspective cohort studyhealth care economics and organizationsAged 80 and overtreatmentImmunosuppressionHematologyMiddle AgedFACTOR-VIII INHIBITORAcquired hemophilia; Demographics; Diagnosis; Outcome; Registry; Treatment; Aged; Aged 80 and over; Autoantibodies; Chi-Square Distribution; Europe; Factor VIII; Female; Hemostatic Techniques; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Pregnancy; Prospective Studies; Registries; Risk Assessment; Risk Factors; Treatment Outcome; Hemophilia A; HemorrhageAutoantibodieEuropeTreatment Outcomeacquired hemophilia; demographics; diagnosis; outcome; registry; treatmentoutcomeINTRAVENOUS GAMMA-GLOBULINFemaleacquired hemophiliaImmunosuppressive AgentsHumanmedicine.medical_specialtyHemorrhageHemophilia AMalignancyRisk Assessmenthemophilia registrydemographicsmedicineHumansMETAANALYSISAutoantibodiesAgedAutoimmune diseasePregnancyChi-Square DistributionFactor VIIIHemostatic Techniquesbusiness.industryRisk FactorAutoantibodymedicine.diseaseSurgeryProspective StudieHemostasisbusinessChi-squared distributionJournal of Thrombosis and Haemostasis
researchProduct

A perioperative uncontrollable bleeding in an elderly patient with acquired hemophilia A: a case report

2013

Key Clinical Message Acquired hemophilia A should be taken into account in the differential diagnosis of perioperative bleeding in patients without any apparent reason for activated partial thromboplastin time prolongation.

bleeding disordersPediatricsmedicine.medical_specialtymedicine.diagnostic_testAcquired hemophilia A; bleeding disorders; bypassing agentsbusiness.industryAcquired hemophilia ASettore MED/41 - AnestesiologiaAcquired hemophilia A bleeding disorders bypassing agents.Case ReportsGeneral MedicinePerioperativehemic and lymphatic diseasesAcquired hemophiliaMedicineIn patientDifferential diagnosisbusinessElderly patientbypassing agentsPartial thromboplastin time
researchProduct

Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario

2019

medicine.medical_specialtyVenous thrombosisbusiness.industryInternal medicineAcquired hemophiliaAcquired haemophilia high inhibitor venous thrombosisMedicineGeneral MedicinebusinessBypassing agentmedicine.diseaseGastroenterologyAnnals of Hematology & Oncology
researchProduct

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

2013

Abstract Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII:C). Immunosuppressive treatment may result in remission of disease over a period of days to months. Until remission, patients are at high risk of bleeding and complications from immunosuppression. Prognostic parameters to predict remission and the time needed to achieve remission could be helpful to guide treatment intensity, but have not been established so far. GTH-AH01/2010 was a prospective multicenter cohort study using a standardized immunosuppressive treatment protocol. The primary study endpoint was time to achieve partial remission (PR, def…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionCell BiologyHematologyOff-label useBiochemistryHemophiliasInterquartile rangeInternal medicineImmunologyAcquired hemophiliamedicineHemotherapyRituximabbusinessCohort studymedicine.drugBlood
researchProduct

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

2015

Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII). Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of patients over a period of days to months. IST is associated with frequent adverse events, including infections as a leading cause of death. Predictors of time to remission could help guide IST intensity but have not been established. We analyzed prognostic factors in 102 prospectively enrolled patients treated with a uniform IST protocol. Partial remission (PR; defined as no active bleeding, FVIII restored >50 IU/dL, hemostatic treatment stopped >24 hours) was achieved by 83% of patients after a median of 31 days (range 7-362…

medicine.medical_specialtybusiness.industryImmunologyHazard ratioAutoantibodyCell BiologyHematologyOdds ratioBiochemistryGastroenterologyConfidence intervalSurgeryhemic and lymphatic diseasesInternal medicinemedicineAcquired hemophiliaAdverse effectbusinessSurvival analysisCause of deathBlood
researchProduct